Two popular medications used in the fight against obesity—semaglutide (Wegovy; Novo Nordisk) and tirzepatide (Zepbound; Eli Lilly)—are priced too high to be considered cost-effective by currently ...

The Dallas Cowboys are obviously lacking a clear-cut starter at running back entering training camp. As the Cowboys prepare to begin training camp on Thursday, July 25, they’ll do so without an ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide 2.4 mg may not be cost-effective for secondary CVD prevention for those with overweight/obesity ...

Please provide your email address to receive an email when new articles are posted on . Tirzepatide and semaglutide may be cost-effective weight loss strategies for patients with knee osteoarthritis ...

Tirzepatide demonstrated superior cost-effectiveness compared to semaglutide for knee OA and obesity, with a $57,400 per QALY threshold. The Osteoarthritis Policy Model assessed cost-effectiveness, ...

Weight loss drugs such as Wegovy and Zepbound are clinically effective but not cost effective at their current prices, according to a study published in JAMA Health Forum. Tirzepatide and semaglutide, ...